Obesity 'bolt-ons' likely to spur pharma M&A in 2024: Analyst

Emily Field, director and head of European pharmaceuticals equity research at Barclays, says the industry is likely to see an uptick in mergers and acquisitions in 2024, especially with smaller deals in the obesity drugs space.